Health ❯ Healthcare ❯ Clinical Trials

Phase 3 Trials

Efficacy Studies Eli Lilly Trials Efficacy and Safety Drug Efficacy Eli Lilly C-POST Trial Randomised Controlled Trials EPCORE FL-1 Trial Vaccine Efficacy DESTINY-Breast09 Trial

FDA Approves Rusfertide (Mimrylo) for Polycythemia Vera

A once-weekly hepcidin-mimetic reducing phlebotomy need with safety concerns including anemia and thrombotic events.

Aficamten Improves Symptoms and Exercise Capacity in Nonobstructive HCM

FDA Approves Lisraya as First Oral Treatment for Adult Dermatomyositis

FDA Approves Zanidatamab Regimens for First‑Line HER2‑Positive Gastroesophageal Cancer

Moderna and Merck Say Phase 3 Personalized mRNA Melanoma Vaccine Met Key Endpoints

Moderna and Merck Report Positive Phase 3 Result for Personalized mRNA Melanoma Vaccine

Moderna and Merck Report Positive Phase 3 Results for Personalized Melanoma Vaccine

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

FDA Panel Rejects Deramiocel Cardiac Claim After Lancet Publishes HOPE‑3 Results

EU Advisers Back Susvimo Implant as New Option for Wet Age‑Related Macular Degeneration

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC

Serum Institute to Build Capacity to Make Investigational TB Vaccine for Gates MRI

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom

FDA Grants Accelerated Approval to Trutakna for IgA Nephropathy

FDA Approves Lumvoa for Thyroid Eye Disease

FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs

FDA Expands Capvaxive Use to At‑Risk Children and Teens

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

FDA Approves Xocova as First Oral Post-Exposure COVID-19 Prophylaxis